Advanced sensing features are coming to wearables beginning in 2025 and Penn State’s device, made with laser-modified ...
People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With ...
Hosted on MSN23h
ABT Stock Jumps 12% Since Q4 Earnings: Time to Invest in Abbott?Abbott Laboratories ABT faced industry-wide challenges that exerted pressure on its profit margins. Factors such as rising ...
This CGM will track your body's response - Could personalised glucose data inform your body’s metabolism and performance?
Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.
AbbottAs a competitive powerlifter, Nathan Zenero has a unique talent for lifting heavy things. He's also taken on more than a few challe ...
Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
The FDA issued an alert warning diabetes patients and caregivers about potential issues with smartphone alerts for continuous ...
The US Food and Drug Administration (FDA) is cautioning patients and caregivers about the potential for not receiving blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback